The Finnish firm unveiled plans to expand its sales and distribution network this week, explaining that the idea is to push its EnPresso reagent-based growth system which is designed to increase protein yield in lab-scale bacterial and yeast expression systems.
A BioSilta spokeswoman told BioPharma-Reporter.com “It’s the right time to fully commercialise BioSilta because we have the first wave of products ready for protein expression and now have the investment to put together our first sales and marketing team.
She explained that BioSilta will target all companies that produce proteins for research use, including biopharmaceutical companies and the services firms that make proteins on their behalf.
“We are in talks with one contract service protein producer who has a project that they have calculated would require them to do 90 litre cultures using LB media for each of 9 proteins. With EnPresso they are looking at reducing this to less than 18 litre cultures to produce the same amount of each protein, which will save them a lot of time and cost.”
The EnPresso system uses BioSilta’s EnBase technology, which is combines long chain polysaccharides with an agent that controls the rate of glucose release to ensure that optimal growth conditions are maintained.
The fundraising round involved existing investors Inveni Capital and Omega Fund Management.